1. Reproducible human efficacy
The strongest signal will be controlled human data showing a meaningful increase in durable terminal hairs—not only laboratory induction or temporary thickening.
2. Persistence across cycles
A result that fades within months has a different commercial profile from a follicle that continues normal cycling. Follow-up duration will shape both clinical value and pricing.
3. Manufacturing consistency
A procedure must work beyond one specialist laboratory. Standardised expansion, quality controls and transport are prerequisites for scaling through clinic networks.
4. A regulator-visible path
Formal trial progression and transparent interaction with major regulators matter more than proposed launch dates. Watch for completed early studies, published results and pivotal trial design.
5. Delivery economics
Even effective cells must be placed efficiently and with natural orientation. Automation, clinic training and cost per treated area will determine whether the result is a boutique procedure or a broadly accessible business.